Peer-reviewed veterinary case report
Low-dose radiation and chemo for treating dog lymphoma
By Lurie, D.M. et al.·Published in Journal of Veterinary Internal Medicine·2009·Veterinary Medical Teaching Hospital, University of California , Davis, CA, United States·View original on Crossref →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Sequential Low-Dose Rate Half-Body Irradiation and Chemotherapy for the Treatment of Canine Multicentric Lymphoma
- Species:
- dog
Plain-English summary
A group of 38 dogs diagnosed with multicentric lymphoma received a combination of low-dose radiation therapy and chemotherapy to treat their cancer. The treatment involved a specific schedule that allowed for a two-week break between radiation sessions. Most dogs showed a good response, with an average first remission lasting about 410 days and a median overall survival of 684 days. This approach appears to be effective, giving many dogs a significant amount of time in remission and improving their overall survival rates.
People also search for: dog lymphoma treatment · canine cancer survival rates · chemotherapy for dogs with lymphoma
Abstract
Abstract Background Sequential half-body irradiation (HBI) combined with chemotherapy is feasible in treating canine lymphoma, but prolonged interradiation intervals may affect efficacy. A 2-week interradiation interval is possible in most dogs receiving low-dose rate irradiation (LDRI) protocols at 6 Gy dose levels. Hypothesis LDRI incorporated into a cyclophosphamide, doxorubicin, vincritine, and prednisone (CHOP)-based chemotherapy protocol is effective for the treatment of lymphoma in dogs. Animals Thirty-eight client-owned animals diagnosed with multicentric lymphoma. Methods Retrospective study evaluating the efficacy and prognostic factors for the treatment of canine lymphoma with sequential HBI and chemotherapy. Results The median 1st remission was 410 days (95% confidence interval [CI] 241–803 days). The 1-, 2-, and 3-year 1st remission rates were 54, 42, and 31%. The median overall survival was 684 days (95% CI 334–1,223 days). The 1-, 2-, and 3-year survival rates were 66, 47, and 44%. Conclusions and Clinical Relevance Results of this study suggest that treatment intensification by a 2-week interradiation treatment interval coupled with interradiation chemotherapy is an effective treatment for dogs with lymphoma.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on Crossref: https://doi.org/10.1111/j.1939-1676.2009.0353.x